56 Although the function of STRN-ALK related with CRC was not studied in vitro, Yakirevich et al. conducted a clinical trial of the ALK inhibitor, ceritinib, which was 20-fold more effective than crizotinib, on a cohort that included a CRC patient positive for STRN-ALK in a pre-clinical setting.17 Ceritinib treatment decreased tumour size of the patient with STRN-ALK, but resistance to ceritinib developed after 9 months.17 Therefore, we also suggest that ALK inhibitors may be provided to patients positive for STRN-ALK as an initial drug. The gene discussed is STRN; the disease is neoplasm.